问：精神分裂长效制剂方面，如何看待来自国内其他微 球厂家的竞争？ 答：丽珠更看重未来整个中国精神分裂长效制剂市场渗 透率的提升和市场规模的增长。抗精分长效针剂是国际 精神分裂治疗指南推荐的一线治疗方案，抗精分长效针 剂在欧美地区的平均使用率达 25%-30%，而我国临床使 用率尚不足 1%。2025 年 9 月，中华医学会精神医学分 会组织推出了《中国精神分裂症防治指南（2025 版）》， 强调了精神分裂疾病长效治疗的重要性，同时肯定了丽 珠的阿立哌唑微球在精神分裂症治疗中的价值。随着新 版《指南》的推出，精神分裂长效制剂的医患认可度将 出现随之提升，长效制剂在中国的渗透率和市场规模也 将显著增长，丽珠的抗精神分裂长效制剂产品的销售也 将随之增加。 丽珠医药集团股份有限公司投资者关系活动记录表 编号：2025-14 |  | □分析师会议 特定对象调研 | | --- | --- | | 投资者关系活动类 | □媒体采访 □业绩说明会 | | | □新闻发布会 □路演活动 | | 别 | □现场参观 | | | □其他 | | | 丽珠集团——董事会秘书 刘宁 | | 活动参与人员 | 丽珠集团——投资者关 ...

Core Insights - The event held on September 11 focused on the performance explanation of Tianjin-listed companies and highlighted the achievements of Lifesun Pharmaceutical in drug development since 2020 [1] Company Developments - Lifesun Pharmaceutical has made significant progress in new product research and development, with multiple drug approvals achieved [1] - The company has received drug registration certificates for 13 generic products, including Valsartan Amlodipine and Rivaroxaban tablets [1] - A total of 22 product specifications have passed consistency evaluations, and 9 chemical raw material drug applications have been approved [1] Market Strategy - The company aims to enrich its product structure and enhance its marketing system, leading to increased product sales and market share [1] - Lifesun Pharmaceutical is committed to deepening the synergy between research and industrialization to provide accessible quality medications for patients while creating long-term value for investors [1]